By Anand Rohatgi, M.D., M.S.C.S., FACC, FAHA
Associate Professor of Internal Medicine
and Kayla A. Riggs, M.D., Internal Medicine Resident
Cholesterol efflux is one of the primary
functions of high-density lipoprotein (HDL) and has been shown to be
independently and inversely associated with incident cardiovascular events.
Inflammation impairs HDL function. A relatively new biomarker of inflammation,
GlycA, has been shown in several large cohorts to be independently associated
with incident cardiovascular events. GlycA is measured through NMR spectroscopy
and is an integrated glycosylation marker of five acute-phase reactants:
alpha1-antitrypsin, haptoglobin, alpha1-antichymotrypsin, alpha1-acid
glycoprotein, and transferrin. We assessed the hypothesis that GlycA is
associated with impaired HDL function measures and that the association between
GlycA and incident cardiovascular events is partially explained by
dysfunctional HDL.
Our study utilized data from the Dallas Heart Study
(DHS), a multiethnic, probability-based population cohort. The primary end
point was first nonfatal MI, nonfatal stroke, coronary revascularization, or
CV death over a median of 11.4 years resulting in 171 events.